OBJECTIVES: Ideal alternatives for replacing native arteries, which have biocompatibility such as growth potential, anti-thrombogenesis and durability, have yet to be discovered. We previously demonstrated the utility of tissue-engineered vascular autografts; however, the use of these autografts is limited to low-pressure conditions. The aim of this study was to create the tissue-engineered arterial patch (TEAP) that could be used in high-pressure systems, and to evaluate the maturation in this regenerative tissue.
INTRODUCTION
In the field of cardiovascular surgery, ideal alternatives for replacing native veins and arteries are yet to be discovered. As a result of >50 years of research, synthetic materials such as expanded polytetrafluoroethylene and Dacron™ (Invista, Wilmington, DE, USA) have been developed; these materials are successfully used as vascular conduits in clinical settings. However, deficiency of growth potential, anti-thrombogenesis, cell affinity and limited durability have restricted the use of these materials in cases involving congenital heart defects or small-diameter grafts. In 1993, Langer and Vacanti proposed the principles of biology and engineering to the development of functional regenerative tissue using three factors: autologous cells, scaffolds (biodegradable polymers) and growthstimulating signals [1] . This new framework has been widely accepted for 'Tissue Engineering' method, and it is expected to overcome the above-mentioned issues because engineered materials could be created and autologous tissues could be used. As a result, many tissue-engineered vascular grafts have been developed and reported [2] [3] [4] .
In our previous studies, we demonstrated the feasibility of tissue-engineered vascular autografts (TEVAs) with autologous cells ( primarily bone marrow cells) and biodegradable scaffolds in a canine inferior vena cava replacement model [5] [6] [7] . Furthermore, we initiated the clinical application of TEVA at our institute from 2000 to 2004, and reported acceptable results [8] [9] [10] [11] . However, our TEVAs were limited to use in low-pressure systems, such as the inferior vena cava or pulmonary artery because we used the polymer scaffold with a polyglycolic acid (PGA) woven fabric sheet, which was rapidly degraded for 8 weeks. Additionally, it is not clear whether TEVA would be durable enough for arterial grafts. Herein, we hypothesized that there is a possibility of creating a tissueengineered vascular material that could be used in high-pressure systems, using a polymer that has a longer degradation period. The aims of this study were (i) to create a polymer scaffold with more durability, (ii) to make a novel tissue-engineered vascular material that could be used in a high-pressure system and (iii) to evaluate the cell proliferation and the maturation in this polymer through an in vivo experiment. We expect this study to be a springboard for further development of optimal arterial grafts that are user-friendly and suitable for use in the clinical setting.
METHODS

Scaffold design and composition
We invented a new biodegradable polymer scaffold that was composed of a copolymer sponge of epsilon-caprolactone and lactide acid [P(CL/LA)] and a poly-L-lactide acid (PLLA) woven fabric sheet, and was manufactured by Gunze Ltd (Kyoto, Japan). P(CL/ LA) was created as a 3D structure, like a sponge that is >80% porous, with a pore diameter of 20-100 μm. It was designed to lose its strength after 16 weeks, and become degraded by hydrolysis after >24 weeks. The PLLA sheet (thickness 0.5 mm) was degraded by hydrolysis after 2 years. With these polymers, we developed a new scaffold that had a three-layer structure: the middle layer comprised the PLLA sheet and both external layers were made of the P(CL/LA) sponge. This new polymer has the following two advantages: (i) P(CL/LA) sponge could provide cell affinity in the early phase after transplantation and (ii) PLLA sheet could be useful in maintaining the strength in the regenerative tissue in high-pressure system. The completed product was adjusted to measure 30 mm × 20 mm in size and 1 mm in total thickness. An ordinary image and a scanning electron microscopy image of this scaffold are shown in Fig. 1 .
In vitro study
We had previously selected a PGA woven fabric sheet for reinforcement in the low-pressure model. Although it was designed to degrade by hydrolysis after 8 weeks, we replaced the PGA sheet with the more durable PLLA sheet. Tensile strength tests were initially performed to investigate whether this novel scaffold had sufficient strength as an alternative vascular material in highpressure systems. The mechanical strength and strain-stress characteristics of this new polymer were profiled by using EZgraph (Shimadzu Co., Kyoto, Japan), and compared with those of a polymer with a PGA sheet for reinforcement. Each of the polymer strips (n = 4) was rectangular in shape (4 mm × 20 mm) with a thickness of 1 mm; these were then pulled to fracture at a stroke rate of 50 mm/min with 15-mm gauge lengths. Furthermore, to compare the strength of these polymers before and after hydrolysis, the PLLA and PGA polymer strips were immersed in distilled water at 37°C for 4 weeks. The mechanical characteristics of the sheets weakened by hydrolysis were measured in the same way as outlined above.
In vivo study
All investigations in animals conformed to both the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication Eighth Edition, 2010) and the standards of the Tokyo Women's Medical University Protocol on Laboratory Animals.
Animal experiment procedure
We used 12 adult beagle dogs (body weight 8.5-9.5 kg) in this study (NARC Corp., Tomisato, Japan). The Animal Care and Use Committee of Tokyo Women's Medical University approved the use of these animals. All dogs were intravenously injected with 250 mg/kg pentobarbital, intubated and mechanically ventilated. Under general anaesthesia, which was maintained with sevoflurane, left lateral thoracotomy was performed through the left fourth intercostal space. After the left subclavian artery was identified, the descending aorta between the distal arch and furcation of the third and fourth intercostal arteries was freed from the surrounding tissue, taking care not to injure the intercostal arteries. Simultaneously, the right inguinal region was dissected and the right femoral artery was isolated. After injecting heparin (0.1 ml/kg), a temporary bypass with a 5-Fr tube (blood flow: more than 300 ml/min) was established from the left subclavian artery to the right femoral artery to avoid paraplegia of the lower extremities caused by clamping of the descending aorta. A crossclamp at the descending aorta was then applied immediately below the branch of the subclavian artery and above the descending aorta at the furcation of the third and fourth intercostal arteries. The aortic vascular wall was longitudinally incised and a 30 mm × 15 mm specimen was resected. We preserved and used these specimens for the control (native arterial tissue) in biochemical examination and reverse transcriptase-polymerase chain reaction (RT-PCR). An oval biodegradable polymer patch of the same size was then anastomosed to the descending aorta with the 6-0 prolene (Asflex, Crownjun Kono, Tokyo, Japan) continuous running suture. After the chest was closed, the dogs were observed for 1, 3 and 6 months (n = 4, each group). They were treated well until euthanization; they did not receive any postoperative anticoagulant therapy.
Evaluations
Macroscopic findings and angiography. At each observation period, angiographies were performed through the contralateral femoral artery, which was used at the time of patch implantation, to confirm the formation of ruptures, stenosis or aneurysms on the implanted patch. The contrast medium used was iohexol (Omnipaque 350; Daiichi-Sankyo Co., Ltd, Tokyo, Japan). At the end of the study, the dogs were euthanized by intravenous injection of pentobarbital. They were then sequentially exsanguinated, and perfused with 1000 ml normal saline to adequately evaluate the endothelium of the regenerative tissues. The implanted patches were extracted rapidly and observed macroscopically.
Histology and immunohistochemistry. Sections of the explanted tissue-engineered arterial patch (TEAP) were immediately fixed in 4% paraformaldehyde, after washing in phosphate-buffered saline, before being embedded in paraffin and cut into 5-μm-thick sections by using a microtome. For histological evaluation, the paraffin sections were stained with haematoxylin-eosin (HE) and modified Masson's trichrome. Immunohistochemical studies were performed by using the Vectastain Elite ABC standard kit or Universal Quick kit (Vector Laboratories, Burlingame, CA, USA). Firstly, to inhibit endogenous peroxidase activity, the sections were pretreated with a solution of 3% hydrogen peroxide in tap water for 5 min, and then incubated for 10 min with prediluted blocking serum. Subsequently, they were incubated with the primary antibody diluted in a buffer containing 1.5% blocking serum for 1 h at room temperature. After rinsing with phosphate-buffered saline, the slides were incubated for 10 min with a diluted biotinylated secondary antibody solution. They were again rinsed with phosphate-buffered saline, and incubated for 30 min with ABC reagent or 5 min with streptavidin/peroxidase complex solution. The immunoreaction was detected with diaminobenzidine. Finally, the slides were counterstained with eosin. The following primary monoclonal antibodies were used: anti-von Willebrand factor (vWF; Dako, Glostrup, Denmark) to label endothelial cells, anti-smooth muscle alpha-actin (αSMA; Dako) to identify the maturation of smooth muscle cells and anti-vascular endothelial growth factor (VEGF; Dako) to confirm the expression of VEGF in TEAP over time. Diluted concentrations of antibodies were used according to the manufacturers' instructions.
Biochemical examination. A 4-hydroxyproline assay was performed to measure the collagen content produced in TEAP, as described previously [12] . The elastin content was determined with the Fastin™ Elastin Assay kit (Biocolor Ltd, Belfast, UK). This assay is a quantitative dye-binding method used for the analysis of elastins extracted from biological materials. The dye label employed is 5,10,15,20-tetraphenyl-21,23-porphine tetra-sulphonate, which combines with the soluble elastin. We used an absolute value of collagen and elastin content per wet weight in this examination to obtain approximate amounts of them in each explanted patch. The levels of collagen and elastin in TEAP were compared with those in native arterial tissues obtained from other dogs (controls).
Semi-quantitative RT-PCR. To genetically evaluate the proliferation and maturation of endothelial and smooth muscle cells in TEAP, the expression of VEGF, vWF and smooth muscle myosin heavy chain (smMHC) mRNA in the explanted patches was determined as a ratio to the ribosome s17 signal, by using semiquantitative RT-PCR as described previously [13, 14] . After the specimen was removed by gently flushing with RNase-free phosphate-buffered saline, nearly one-third of the patch was immediately excised by using RNase-free scissors and forceps to extract the RNA; subsequently, the excised patch was kept in Isogen solution (Nippon Gene, Tokyo, Japan). After homogenization, total RNA was extracted by using the acid guanidine thiocyanate-phenolchloroform method. For RT-PCR, cDNA was synthesized from 5 µg of total RNA with reverse transcriptase (ReverScript® IV; Wako Pure Chemical Industries, Ltd, Osaka, Japan) and oligo(dT) primers (Invitrogen, Carlsbad, CA, USA), according to the manufacturers' instructions.
One microgram of cDNA for VEGF, vWF, smMHC and ribosome s17 was amplified with specific forward and reverse oligonucleotide primers, predenatured for 2 min at 94°C, followed by 31 cycles (VEGF), 38 cycles (vWF), 36 cycles (smMHC) or 26 cycles (ribosome s17) of denaturation (60 s at 94°C for VEGF and 15 s at 94°C for vWF, smMHC and ribosome s17), annealing (60 s at 52°C for VEGF, 15 s at 60°C for vWF, 55°C for smMHC and 53°C for ribosome s17), extension (60 s for VEGF at 72°C and 15 s for vWF, smMHC and ribosome s17 at 72°C) and 1 cycle of final extension for 7 min at 72°C in a single tube by using a GeneAmp® PCR system 2700 Thermal Cycler (Applied Biosystems, Foster City, CA, USA). The following primers were used: (i) VEGF, forward 5'-TTC TGT ATC AGT CTT TCC TGG TG-3', reverse 5'-CGA AGT GGT GAA GTT CAT GGA TG-3'; (ii) vWF, forward 5'-TGG ATG AGC TTT TGC AGA CC-3', reverse 5'-GTG GGA GCC GTC GTG GTA CT-3'; (iii) smMHC, forward 5'-AAA AAG TGA ACT TCT CCA GAA AGA A-3', reverse 5'-TAA CAC AGG GGT AAT GAT CTG AAA-3'; and (4) ribosome s17, forward 5'-GAA GGC CCG GGT CAT CA-3', reverse 5'-GTA GGC TGA GTG ACC TG-3'. All primer pairs crossed at least one intron. The sizes of the RT-PCR products for VEGF, vWF, smMHC and ribosome s17 were 570, 432, 154 and 340 base pairs, respectively. RT-PCR products were analysed with an Agilent 2100 Bioanalyzer® and the DNA 1000 LabChip® kit (Agilent Technologies, Palo Alto, CA, USA). The expression of VEGF, vWF and smMHC was calculated as a ratio to ribosome s17 mRNA, which was measured as an internal standard, in the same samples. The expression of these mRNAs was compared between the observation period groups as well as with native descending aorta specimens obtained from the same dog.
Statistical analysis
All results were expressed as mean ± standard error. Statistical analysis was performed with StatView version 5.0 (Abacus Concepts, Inc., Berkeley, CA, USA) following the 'Guidelines for data reporting and nomenclature' (Ann Thorac Surg 1988). Strain-stress examinations were analysed with the Student's t-test. The Kruskal-Wallis one-way analysis of variance with the Dunn's post hoc test was performed to compare measured data among multiple groups. A P-value <0.05 was considered statistically significant.
RESULTS
In vitro study
The strain-stress relation curve between PGA and PLLA is shown in Fig. 2 . The tensile strength of the PGA polymer remarkably decreased after 1 month of hydrolysis. In contrast, the tensile strength of the new PLLA polymer remained sufficient even after hydrolysis. The maximum tensile strength value for PGA decreased to about one-tenth of the original after hydrolysis because of its rapid degradation compared with PLLA. The stress tests of the polymer showed identical results.
In vivo study
Macroscopic findings and angiography. All animals survived until the designated observation end-points. Angiographies performed at each observation end-point showed no evidence of stenosis or dilatation with turbulence of blood flow around TEAP. Macroscopic findings of each explanted TEAP showed no intimal hyperplasia or aneurysm formation (Fig. 3) . No thrombus was observed. The inner sides of TEAP were covered with native intima-like tissue with a smooth surface, which we assumed was the endothelium. These tissues were observed at 1 month after implantation, although the cell layers were very thin. At 6 months after implantation, however, it was clear that the cell layers had gradually increased and matured.
Histology and immunohistochemistry. Histological studies
with HE and Masson staining at 1 month after implantation revealed good cell and tissue proliferation in TEAP (Fig. 4) . However, many white and blank spaces were simultaneously observed in the patches, which indicated the presence of residual polymer [P(CL/LA) . Very few extracellular matrices, such as collagen and elastin fibres, were present in TEAP at 1 month. However, at 3 and 6 months, the blank spaces (residual sponge polymer) were occupied by cellular components and extracellular matrices, and maturation of TEAP was evident. In the immunohistochemical studies, the luminal surfaces of the patches at 1 month were covered with a single layer of endothelial cells stained with antibodies to vWF. The vWF-positive cells were also visible beneath the layer of endothelial cells (within the regenerated media) at 1 month; however, at 3 and 6 months, the cells accumulated more clearly on the luminal surfaces of TEAP. αSMA-positive cells were observed in the media of the regenerated tissue; they gradually increased over time. VEGF expression in the patches was observed on both the luminal surfaces and within the media at 1 month after implantation; however, no VEGF expression was detected at 3 and 6 months ( Fig. 4 ).
Biochemical examination. The results of the biochemical examination are shown in Fig. 5 . The 4-hydroxyproline assay demonstrated the presence of collagen in TEAP at each observation end-point. This gradually increased over time to reach the level of native arterial tissue. However, at 3 and 6 months after implantation, the collagen levels were higher than those of the native tissue (1 month: 14.0 ± 4.90 µmol/g, 3 months: 79.8 ± 1.96 µmol/g, 6 months: 88.0 ± 16.4 µmol/g, native: 54.3 ± 3.21 µmol/g). The elastin content also increased over time; however, it only reached 40% of that of the native arterial tissue at 6 months after implantation (1 month: 4.16 ± 0.49 mg/g, 3 months: 5.09 ± 1.07 mg/g, 6 months: 7.50 ± 0.49 mg/g, native: 19.0 ± 2.13 mg/g).
Semi-quantitative RT-PCR. The concentration ratios for mRNA expression of each of the measured factors in TEAP, namely VEGF/ ribosome s17, vWF/ribosome s17 and smMHC/ribosome s17, were measured and graphed for each group (Fig. 6 ). In terms of VEGF mRNA, PCR products for three variants, namely VEGF121, VEGF164 and VEGF188, were detectable in TEAP. Therefore, VEGF expression was compared by using the concentration ratio of VEGF164/ribosome s17. The expression of VEGF164 mRNA in TEAP at 1 month was significantly higher than that of native arterial tissue (P < 0.05); it gradually decreased to the same level as that of native tissue within 6 months (1 month: 0.124 ± 0.017 ng/µl, 3 months: 0.068 ± 0.003 ng/µl, 6 months: 0.007 ± 0.002 ng/µl, native: 0.009 ± 0.003 ng/µl). vWF mRNA expression at 1 month was significantly higher than that of regenerative tissue at 3 months (P < 0.05); it was low at 3 months but increased thereafter to reach the same level as native tissue at 6 months (1 month: 1.002 ± 0.240 ng/µl, 3 months: 0.426 ± 0.051 ng/µl, 6 months: 0.631 ± 0.127 ng/µl, native: 0.834 ± 0.191 ng/µl). The expression of smMHC mRNA gradually increased over time but was less than 60% of that of native tissue at 6 months after implantation (1 month: 0.309 ± 0.029 ng/µl, 3 months: 0.336 ± 0.057 ng/µl, 6 months: 0.351 ± 0.028 ng/µl, native: 0.540 ± 0.027 ng/µl).
DISCUSSION
We previously demonstrated the advantages of TEVAs with autologous cells, primarily mononuclear bone marrow cells and biodegradable scaffolds in a canine inferior vena cava replacement model. Histological examination revealed that mononuclear bone marrow cells seeded onto a scaffold, proliferated and differentiated in TEVAs after implantation and resulted in endothelialization, smooth muscle cell generation and growth factor production. We recently reported the results of the biochemical investigations of endothelial cell function in TEVAs, as well as the mechanical properties and characteristics of TEVAs [15] . On the basis of these experimental studies, we initiated the clinical application of TEVA, and were confident of good mid-term results. However, the use of this autograft was limited to only low-pressure systems such as the inferior vena cava or pulmonary artery. An attempt to implant the polymer that we used during the low-pressure studies into the canine ascending aorta resulted in aneurysm formation [12] . On the basis of this result, we speculated that the polymer used under the low-pressure conditions did not have sufficient strength in the artery because of its rapid degradation. Therefore, in the present study, we developed a new biodegradable scaffold made from the more durable PLLA polymer, and proved that this new polymer had the potential tensile strength required during in vitro experiments. We then demonstrated that this novel scaffold could be used as tissue-engineered vascular material in high-pressure systems.
In this study, we focused our experiments on endothelialization and maturation of the media layer in TEAP. The luminal surface of the explanted TEAP was covered with endothelium; this was proved macroscopically and immunohistologically because the specimens were stained with antibodies to vWF at 1 month after implantation. The endothelium matured more clearly over time, as could be seen at the 3-and 6-month observation end-points. Furthermore, immunohistochemical staining also showed simultaneous VEGF production in TEAP at 1 month after implantation. In addition, the expression of VEGF mRNA was significantly elevated at 1 month after implantation in the RT-PCR results. It is well known that VEGF, which enhances endothelial cell migration or proliferation and promotes its differentiation, is produced and secreted by the endothelial cells, smooth muscle cells, fibroblast cells and circulating endothelial progenitor cells in vasculogenesis and angiogenesis [16] . Consequently, we speculated that this dynamic change indicates that VEGF may play a crucial role in endothelialization of TEAP, particularly during the early phase after implantation. With regard to where VEGF was synthesized or what it was produced from in TEAP at 1 month after implantation, we hypothesize the following: primarily, the endothelial and smooth muscle cells migrate from the native vascular wall tissue across the anastomosis of the patch to produce and secrete VEGF as a result of autocrine signalling and promote tissue generation in TEAP. We previously demonstrated that VEGF is produced by seeded bone marrow cells in the biodegradable scaffold in an in vivo canine model [7] . Therefore, we consider it significant that the tissue-engineered arterial tissue in this study was obtained without the help of autologous cells.
As far as maturation of the media is concerned, histological studies of HE and Masson staining at 1 month after implantation showed good cell and tissue proliferation in TEAP. αSMA-positive cells (assumed to be smooth muscle and/or fibroblast cells) and extracellular matrices such as collagen fibres were observed during the immunohistochemical study. However, many white and blank spaces that indicated some residual polymer [P(CL/LA)] sponge were observed simultaneously at 1 month after implantation. On the other hand, at 3 and 6 months, these spaces were gradually occupied by cellular components and extracellular matrices. These findings reveal that the TEAP media matured over time. Meanwhile, biochemical results showed that collagen fibres were produced in TEAP and they increased gradually. At 3 and 6 months after implantation, the level of collagen in TEAP was higher than the native level. This result suggests that there were not many cellular components in TEAP but rather more extracellular matrices. Furthermore, although the elastin content increased with time, it reached only 40% of that of the native arterial tissue, even at 6 months after implantation. Elastin is produced by smooth muscle cells, which were represented in the media layer; we speculated that regeneration of smooth muscle cells was limited in TEAP. The smMHC RT-PCR results support this contention. The expression of smMHC mRNA gradually increased over time; however, the expression level was below 60% of that of native tissue at 6 months after implantation. To classify the phenotype of the smooth muscle cells in TEAP, we identified differentiated and undifferentiated smooth muscle cells by using immunostaining with anti-SM2 and anti-SMemb antibodies, respectively [17] . These antibodies are isoforms of the MHC. SMemb-positive cells were confirmed in TEAP at 1 month; however, they were not detected at 6 months. SM2-positive cells, the marker for mature smooth muscle cells, were not confirmed at any time point (data not shown). These results provide further proof of our hypothesis. We assume that cell proliferation and migration to the polymer during the early phase after implantation, especially by the smooth muscle cells, is the most important factor for maturation of media in this new scaffold.
In the past decade, many articles of regenerative blood vessels have been reported to obtain an ideal tissue, which is as similar to native vasculature as possible. Niklason et al. reported a novel tissue-engineered blood vessel using a tubular synthetic biodegradable scaffold composed of PGA and seeded with various smooth muscle cells under arterial circulation [18, 19] . They also attempted to replace other cell sources such as human bone marrow-derived mesenchymal stem cells and cadaveric aortic smooth muscle cells [20, 21] . By using a biodegradable polymer and autologous cells in the same way as we did, we are convinced Figure 5 : The collagen content of explanted tissues at 1, 3 and 6 months after implantation (n = 4) gradually increased over time. It was higher than the native tissue level at 3 and 6 months after implantation. Although the elastin content also increased over time, it only reached 40% of the native tissue level at 6 months after implantation. that this is a great opportunity to create regenerative blood vessels using only autologous tissue without remaining foreign material in the body. However, basically in their process of making tissueengineered blood vessels, the grafts were cultured for 8 weeks in vitro, and additionally, needed to be kept under pulsatile flow conditions, as in a bioreactor, to obtain sufficient strength for the artery. They also simultaneously proposed that extending the degradation period of the polymer to increase durability results in interference between the residual polymer and the proliferation of media because of the lack of a scaffold [22] . Further optimization of the polymer composition including the issue of the degradation period is needed. Meanwhile, L'Heureux et al. utilized autologous fibroblasts from human adults using the method of sheet-based tissue engineering [23, 24] . By rolling self-assembled fibroblast sheets into the many distinct layers, they constructed human tissue-engineered blood vessels, which have extremely satisfactory mechanical properties. Recently, they reported the impressive of this grafts in clinical application with good patency and durability in high-pressure systems [25] . On the other hand, it seems that it takes 6-9 months to obtain the regenerative tissue, and additionally, it has no growth potential. Although there is a difference between the vasculature and the patch, we are considering that there could be some advantages of our TEAP in terms of both cell proliferation and growth potential.
In the field of cardiovascular surgery, especially in congenital heart disease, the use of synthetic materials is not popular yet because of their lack of growth potential, anti-thrombogenesis, cell affinity and limited durability. Further investigation, not only for basic science but also for translational research, is needed to obtain more mature regenerative tissue that could be used in high-pressure systems.
CONCLUSIONS
We developed a new biodegradable polymer scaffold, and demonstrated the maturation of endothelial and smooth muscle cells in TEAP. This novel biodegradable polymer scaffold could be used as an alternative vascular material even in high-pressure systems.
